Spots Global Cancer Trial Database for SHOX2_PTGER4 DNA Methlyation in Lung Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: SHOX2_PTGER4 DNA Methlyation in Lung Cancer
Official Title: Establishing a Non-invasive Diagnostic Biomarker Test for Early Diagnosis of Lung Cancer
Study ID: NCT04321499
Conditions
Interventions
Study Description
Brief Summary: Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included. SHOX2 and PTGER4 will be analyzed via PCR.
Detailed Description: Data on SHOX2 and PTGER4 DNA Methylation suggest possible use as a biomarker for early lung cancer diagnosis. In this study a control group consisting of COPD patients with a CT-scan of the chest no older than 6 weeks and a control group of patients with a nodule and ruled out diagnosis of lung cancer will be included. A total of 150 patients will be enrolled in this study. SHOX2 and PTGER4 will be analyzed via PCR of blood plasma samples.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ruhrlandklinik, Department of Interventional Pneumology, Essen, NRW, Germany
Contact Details
Name: Kaid Darwiche, MD
Affiliation: head of deparment of interventional pneumology, Ruhrlandklinik, UHEssen
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
